RPTX Repare Therapeutics Inc

Price (delayed)

$3.48

Market cap

$147.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$47.27M

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled ...

Highlights
RPTX's quick ratio has surged by 99% year-on-year and by 35% since the previous quarter
RPTX's debt is down by 45% year-on-year and by 19% since the previous quarter
Repare Therapeutics's gross profit has soared by 91% from the previous quarter but it has decreased by 29% YoY
Repare Therapeutics's revenue has soared by 91% from the previous quarter but it has decreased by 29% YoY

Key stats

What are the main financial stats of RPTX
Market
Shares outstanding
42.45M
Market cap
$147.71M
Enterprise value
$47.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.63
Price to sales (P/S)
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.48
Earnings
Revenue
$97.86M
EBIT
-$58.06M
EBITDA
-$53.84M
Free cash flow
-$84.9M
Per share
EPS
-$1.09
Free cash flow per share
-$2.01
Book value per share
$5.5
Revenue per share
$2.32
TBVPS
$6.23
Balance sheet
Total assets
$263.08M
Total liabilities
$31.13M
Debt
$2.78M
Equity
$231.95M
Working capital
$224.1M
Liquidity
Debt to equity
0.01
Current ratio
8.33
Quick ratio
7.86
Net debt/EBITDA
1.87
Margins
EBITDA margin
-55%
Gross margin
100%
Net margin
-46.7%
Operating margin
-72.3%
Efficiency
Return on assets
-16.5%
Return on equity
-19.8%
Return on invested capital
-45.5%
Return on capital employed
-25%
Return on sales
-59.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RPTX stock price

How has the Repare Therapeutics stock price performed over time
Intraday
-1.97%
1 week
9.78%
1 month
-12.78%
1 year
-68.39%
YTD
-52.33%
QTD
5.45%

Financial performance

How have Repare Therapeutics's revenue and profit performed over time
Revenue
$97.86M
Gross profit
$97.86M
Operating income
-$70.73M
Net income
-$45.69M
Gross margin
100%
Net margin
-46.7%
RPTX's net margin has dropped by 119% year-on-year but it has surged by 75% since the previous quarter
Repare Therapeutics's gross profit has soared by 91% from the previous quarter but it has decreased by 29% YoY
Repare Therapeutics's revenue has soared by 91% from the previous quarter but it has decreased by 29% YoY
Repare Therapeutics's operating margin has surged by 68% QoQ

Growth

What is Repare Therapeutics's growth rate over time

Valuation

What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.63
P/S
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.48
RPTX's EPS has plunged by 58% YoY but it has soared by 51% from the previous quarter
The P/B is 78% below the 5-year quarterly average of 2.8 and 61% below the last 4 quarters average of 1.6
The equity has grown by 9% from the previous quarter but it has contracted by 8% YoY
Repare Therapeutics's revenue has soared by 91% from the previous quarter but it has decreased by 29% YoY
The P/S is 69% lower than the last 4 quarters average of 4.9

Efficiency

How efficient is Repare Therapeutics business performance
The ROA has plunged by 101% YoY but it has grown by 48% from the previous quarter
RPTX's return on equity has dropped by 80% year-on-year but it has surged by 50% since the previous quarter
RPTX's ROS has soared by 71% from the previous quarter
Repare Therapeutics's ROIC has increased by 43% from the previous quarter

Dividends

What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RPTX.

Financial health

How did Repare Therapeutics financials performed over time
The current ratio has soared by 107% YoY and by 33% QoQ
RPTX's quick ratio has surged by 99% year-on-year and by 35% since the previous quarter
RPTX's debt is 99% smaller than its equity
The debt to equity has dropped by 50% since the previous quarter and by 50% year-on-year
RPTX's debt is down by 45% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.